Update on new immunomodulatory agents.
Myers
S A
SA
Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D012871:Skin Diseases / Q000188:drug therapy*; D016559:Tacrolimus / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013792:Thalidomide / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D013792:Thalidomide; C058028:immunomycin; D009173:Mycophenolic Acid; D016559:Tacrolimus